Crohn’s Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...
pharmaphorum1d
Partnering to innovate: UCB pharma
Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...
FiercePharma8d
Rapid growth spurt for UCB's Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approval
It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...
The American Journal of Managed Care8d
FDA Approves Bimekizumab in Hidradenitis Suppurativa
This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...
ClearPoint Neuro (NASDAQ:CLPT) vs. West Pharmaceutical Services (NYSE:WST) Head to Head Survey
ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both medical companies, but which is the superior business? We will compare the two ...
Future Market Insights1h
Drug Discovery Services Market Set for Remarkable Growth, Projected to Reach USD 76.5 Billion by 2033 at a 14.5% of CAGR
Drug Discovery Services Market. The global drug discovery services market is poised for significant expansion, with a ...
The Pharma Letter15d
UCB and Biogen’s dapirolizumab pegol paves new path for SLE treatment
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...
https//businessnewswales.com9h
New £22.4 Million Bioscience Grant for Training Programme Involving Swansea University
Swansea University has helped secure £22.4 million in funding from the Biotechnology and Biological Sciences Research Council ...
UCB SA (0NZT) Receives a Buy from Barclays
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
pharmaphorum1d
Executive perspectives: Dr Roch Doliveux
Continuing our series speaking to senior executives who are transforming the pharma business model, pharmaphorum catches up with Dr Roch Doliveux, CEO of UCB, to find out what is the key to ...